Organic sales growth:
Q4, 2023: 29% (-17)
EBITDA margin:
Q4, 2023: 36% (32)
October 1 - December 31, 2023
Net sales increased by 32% (-7) to SEK 201 m (152).
Sales increased organically by 29% (-17), currency effect 3% (10).
EBITDA increased to SEK 73 m (48).
EBITDA margin amounted to 36% (32).
Profit before tax increased to SEK 63 m (40).
Earnings per share before and after dilution increased to SEK 2.11 (1.35).
Cash flow from operating activities increased to SEK 76 m (28).
The Board of Directors proposes a dividend of SEK 2.25 per share for 2023 (2.25).
Significant events after the period close
CellaVision and Sysmex Corporation ("Sysmex") have announced a Strategic Alliance Agreement to reinforce and extend their joint leadership position within hematology and seize new opportunities for optimized diagnostics.
Contact
Adele Horn
Corporate Communications & Investor Relations Manager
Tel: + 46 46 460 26 04
www.cellavision.com
adele.horn@cellavision.com
About Us
CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 13 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com
This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-07 07:20 CET.
